FundingMachine

For the work you are building

Discover.
Develop. Submit.

One evidence base from the first funding search to the regulatory file.

Find the programme. Read the conditions.
Make the decision with its source in view.

Biotech foundersPrincipal investigatorsGrant consultancies

Funding Atlas / Eligibility screen

Start with your work.

Check the released programme rules. No account required.

Encoded rules only, not a funder decision. Additional financial or study evidence may be needed. Amount is compared with the published planning cap, not a guaranteed award.

Programme rules load after you focus or point to this screen. No profile facts are sent.

The funding landscape

Where your next
question begins.

Explore the records. Then check the applicant conditions behind the map.

Released Funding Atlas dot-matrix world map. Counts are by funder jurisdiction, not applicant eligibility.
Programmes by funder jurisdiction. Location is not applicant eligibility. European Union and Global scope are listed separately. Source snapshot: . Map methodology
United States 28European Union 20United Kingdom 10Austria 5Australia 5Germany 5Canada 3Netherlands 3Ireland 2Switzerland 1Denmark 1France 1Norway 1Poland 1Singapore 1Global scope 1
88Programmes
15Jurisdictions
65Funders
47Deadlines ahead

Awards up to USD 34.5m per programme. Figures as of 3 October 2026, from the funders' published pages.

Figures as of , from the funders' published pages. Deadline count is the release snapshot, not today's calendar.

Nearest dated source-backed opportunity

KMU-innovativ: Biomedizin

German Federal Ministry of Research, Technology and Space (BMFTR, formerly BMBF), through Projektträger Jülich

Outline sketches close ·

Confirm current call scope and eligibility on the original funder page. Source checked 2 Oct 2026.

One evidence base

From the first question
to the final file.

Explore what you can use today, and the connected work being built around it.

01

Discover

Funding Atlas

Find programme records relevant to your organisation and development stage. Compare the encoded rules, keep a local shortlist and open the funder source.

Available
02

Design

Specialist Advisors

Explore the questions your scientific and regulatory strategy needs to answer. Planned software reasoning would link those questions to evidence for a person to review, not replace an expert.

Planned
03

Assemble

Consortium Builder

Understand the roles and scopes a proposed project needs. Planned role mapping would distinguish sourced profiles and cost references from actual partners, capacity or quotations.

Planned
04

Build

Application Builder

Check your draft against the company facts and evidence behind it. The internal workflow identifies unsupported statements for your work list; you remain the author and decide every change.

In development
05

Document

Regulatory Document Engine

Bring protocol, investigator, CMC and quality evidence into a reviewable package. Planned source-traced sections support human review, not compliance certification or regulatory filing.

Planned
06

Submit

Submission Desk

Prepare a handoff for the authority and channel your submission requires. The planned desk does not file, act as a legal representative or remove your responsibility for the final submission.

Planned

The evidence behind the journey

Three records.
A deeper view.

Each data layer is in development. Nothing is published until its first release.

Award history

Who funded work
like yours?

Published awards by funder, connected to Atlas programmes. Each source's licence is read and recorded before release.

In development

Trial outcome record

What happened
to the asset?

Registered trial outcomes and reasons from registries and regulator documents, with the asset's attempt history. Nothing is published until its first release.

In development

Dated Build log entry is not yet published.

Market record

What does the public
record show?

Prices, public volumes, exclusivity and disclosed sales from public sources. Nothing is published until its first release.

In development

Dated Build log entry is not yet published.

Build / Method in practice

The evidence came first.
The person made the call.

A clinical-stage company measured its draft funding application against its own evidence base and received a work list of unsupported statements before submission. The person decided every change.

In development

Method only. No internal results or measurement figures are published.

General enquiry

Tell us about your programme.

The form records a general enquiry. It is not a submission request or access to a planned stage.

NW PharmaTech Ltd uses your details to respond as described in the privacy notice. What the enquiry form does.

Preparing secure form